All data in the meta-analysis are from published studies.

Introduction {#sec001}
============

Sjögren syndrome (SS) is a common autoimmune disease with a prevalence of 0.1% to 4.8% \[[@pone.0116744.ref001]\], which predominantly affects women. SS is a systemic disease, which can involve extraglandular organs, including the characteristic clinical features, dry eyes and dry mouth.

Autoantibodies usually serve as biomarkers for the diagnosis and prognosis of autoimmune diseases; in the diagnosis of SS the SSA and SSB autoantibodies play an important role. However, anti-SSA and anti-SSB antibodies are present in only 33--74% and 23--52% of SS patients, respectively \[[@pone.0116744.ref002]\]. In order to identify a greater proportion of cases of SS using laboratory methods, other autoantibodies, including muscarinic receptor type 3 (M3R) autoantibodies have been explored, with a view to establishing their value in the diagnosis of SS.

Muscarinic receptors are G-protein coupled acetylcholine receptors, present in plasma membranes of certain neuronal cells \[[@pone.0116744.ref003]\]. The anti-M3R antibody targets the M3R subtype; effects of this targeting are considered to result in elements of the pathophysiology of SS, such as impaired saliva secretion \[[@pone.0116744.ref004]\]. Over the past decade, numerous studies have explored the value of anti-M3R antibodies in the process of diagnosing SS. However, inconsistent conclusions relating to the diagnostic performance of anti-M3R antibodies have been drawn \[[@pone.0116744.ref005]--[@pone.0116744.ref015]\]. The aim of this study was to systematically review the literature to determine the diagnostic performance of anti-M3R antibodies in patients with SS.

Methods {#sec002}
=======

Literature search {#sec002a}
-----------------

A comprehensive search of MEDLINE, EMBASE, ISI web of knowledge, and The Cochrane Library was undertaken, using the following terms; "muscarinic receptor type 3 OR M3R" and "Sjögren syndrome OR SS". No limits were placed on ethnicity or geographic region, and all documents were updated to August 2014. Additional relevant references cited in searched articles were also selected.

Eligibility criteria {#sec002b}
--------------------

Studies meeting the following criteria were eligible for inclusion; (1) assessed the diagnostic accuracy of testing for M3R autoantibodies in SS; (2) sufficient data reported to construct two-by-two tables; (3) testing of M3R autoantibodies by enzyme-linked immunosorbent assay; (4) there is no criteria for published language; (5) studies based on animal or cell cultures, case reports and conference abstracts without subsequent publication in full text were excluded. In the case of overlapping studies, only the study with the largest sample size was included in our analysis.

Data extraction {#sec002c}
---------------

Data was extracted from all selected studies by 2 independent investigators. Inter-researcher disagreements were resolved by consensus, or by a third investigator. The following data was collected from each selected study; first author's name; publication year; country in which the study was performed; study results; detecting peptide; coupling of peptide; confirmation of peptide and diagnosis criteria. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool. Authors of the identified studies were contacted via e-mail if further study details were needed.

Statistical analysis {#sec002d}
--------------------

Statistical analysis was performed using STATA 11.2 software (Stata Corporation, College Station, TX, USA) and Meta-DiSc 1.4 (Unit of Clinical Biostatistics, Ramony Cajal Hospital, Madrid, Spain). The heterogeneity was evaluated by Cochran's *Q*-statistic, as well as the *I^2^*-statistic; a P value \>0.10 in *Q*-statistic, or *I^2^* \<50% in *I^2^*-statistic, indicated lack of heterogeneity. Finally, the overall or pooled diagnostic odds ratio (DOR), sensitivity, specificity, positive likelihood ratio (LR+) and negative likelihood ratio (LR--), and their 95% CI, was obtained by a mixed-effects model, in the presence (P≤0.10 or *I^2^*\>50%) or absence (P\>0.10 and *I^2^*≤50%) of heterogeneity, respectively. The area under the summary receiver operating characteristic (SROC) curves represented the overall performance of the detection method. A P value \<0.05 (two-sided) was considered as significant. Evaluation of multiple regression analysis and publication bias was also undertaken.

Results {#sec003}
=======

Literature search {#sec003a}
-----------------

Electronic and manual searches yielded a total of 69 potentially eligible articles. A flow chart of screening articles for meta-analysis is illustrated in [Fig. 1](#pone.0116744.g001){ref-type="fig"}. Fifty-six articles were excluded by screening the titles and abstracts. A further 4 articles were excluded following more detailed assessment (2 review articles, 1 duplicated article, 1 irrelevant article). A total of 11 eligible studies were included in the meta-analysis \[[@pone.0116744.ref005]--[@pone.0116744.ref015]\].

![Flow chart of studies included in the meta-analysis.](pone.0116744.g001){#pone.0116744.g001}

Study characteristics {#sec003b}
---------------------

The characteristics of the 11 studies are summarized in [Table 1](#pone.0116744.t001){ref-type="table"}. A total of 965 SS patients and 1289 controls were involved in these studies. With regards to the geographic location of the studies, 6 were carried out in Asia \[[@pone.0116744.ref006]--[@pone.0116744.ref008], [@pone.0116744.ref010], [@pone.0116744.ref011], [@pone.0116744.ref014]\], 3 in European \[[@pone.0116744.ref005], [@pone.0116744.ref012], [@pone.0116744.ref013]\], and 2 in America \[[@pone.0116744.ref009], [@pone.0116744.ref015]\]. Assessment using QUADAS indicated that the studies were of high quality, with positive results for at least 7/14 items ([Fig. 2](#pone.0116744.g002){ref-type="fig"}).

10.1371/journal.pone.0116744.t001

###### Characteristics of studies included in the meta-analysis of diagnostic performance of anti-M3R antibody in SS.

![](pone.0116744.t001){#pone.0116744.t001g}

  **Author**                                      **Year**   **Region**   **TP**   **FP**   **FN**   **TN**   **Diagnosis criteria**                                 **Peptide used for detection**                                                           **QUADAS Scores**
  ----------------------------------------------- ---------- ------------ -------- -------- -------- -------- ------------------------------------------------------ ---------------------------------------------------------------------------------------- -------------------
  Deák et al.\[[@pone.0116744.ref005]\]           2012       Hungary      31       4        45       46       the 2002 American-European Consensus Criteria for SS   AGSE from the second extracellular loop of the receptor                                  13
                                                                          31       3        45       47                                                              YNIP from the third extracellular loop of the receptor                                   
                                                                          13       4        63       46                                                              TRIC from the third intracellular loop of the receptor                                   
                                                                          57       21       19       29                                                              GST-AGSE fusion peptide                                                                  
                                                                          66       0        10       50                                                              GST-YNIP fusion peptide                                                                  
                                                                          26       1        50       49                                                              BSA-AGSE multiple-conjugated peptide                                                     
  He et al.\[[@pone.0116744.ref006]\]             2012       China        69       34       31       106      the 2002 American-European Consensus Criteria for SS   circular peptide from the second extracellular loop sequence of muscarinic receptors     13
  He et al.\[[@pone.0116744.ref007]\]             2011       China        92       12       56       207      the 2002 American-European Consensus Criteria for SS   circular peptide from the second extracellular loop sequence of muscarinic receptors     13
                                                                          83       35       65       184                                                             linear peptide from the second extracellular loop sequence of muscarinic receptors       
  Tsuboi et al.\[[@pone.0116744.ref008]\]         2010       Japan        18       2        24       40       the Japanese Ministry of Health criteria for SS        peptide antigens of the N-terminal region                                                12
                                                                          20       3        22       39                                                              peptide from the first extracellular loop sequence of muscarinic receptors               
                                                                          23       1        19       41                                                              peptide from the second extracellular loop sequence of muscarinic receptors              
                                                                          19       1        23       41                                                              peptide from the third extracellular loop sequence of muscarinic receptors               
  Roescher et al.\[[@pone.0116744.ref009]\]       2011       America      5        2        66       35       the 2002 American-European Consensus Criteria for SS   KRAI peptide from the second extracellular loop sequence of muscarinic receptors         12
                                                                          5        1        66       36                                                              MAP KRAI multi-antigenic peptide versions KRAI                                           
                                                                          4        1        67       36                                                              Kc_c citrullinated and cyclised loop 2                                                   
                                                                          3        1        68       36                                                              Loop 1 peptide from the first extracellular loop sequence of muscarinic receptors        
  Wu et al.\[[@pone.0116744.ref010]\]             2008       China        33       13       37       113      the 2002 American-European Consensus Criteria for SS   not report                                                                               13
  Nakamura et al.\[[@pone.0116744.ref011]\]       2008       Japan        20       2        18       74       not report                                             peptide from the second extracellular loop sequence of muscarinic receptors              11
  Kovács et al.\[[@pone.0116744.ref012]\]         2005       Hungary      70       31       49       126      the 2002 American-European Consensus Criteria for SS   GST-KRSE， peptide from the second extracellular loop sequence of muscarinic receptors   13
  Marczinovits et al.\[[@pone.0116744.ref013]\]   2005       Hungary      39       0        1        40       the 2002 American-European Consensus Criteria for SS   GST-KRSE， peptide from the second extracellular loop sequence of muscarinic receptors   12
  Naito et al.\[[@pone.0116744.ref014]\]          2005       Japan        25       4        199      326      the Japanese Ministry of Health criteria for SS        peptide from the second extracellular loop sequence of muscarinic receptors              13
  Bacman et al.\[[@pone.0116744.ref015]\]         2001       Argentina    32       5        5        68       the 1993 European Community Criteria for SS            peptide from the second extracellular loop sequence of muscarinic receptors              12

![The quality assessment of included studies based on the QUADAS tool.](pone.0116744.g002){#pone.0116744.g002}

Meta-analysis {#sec003c}
-------------

The sensitivity of anti-M3R antibody testing ranged from 4%- 98%; reported specificity ranged from 58%- 100%. A mixed-effects model was used for the meta-analysis (P \<0.001, *I* ^2^ = 99%). The pooled DOR was 13.00 (95% CI, 2.00--100.00). The sensitivity was 0.43 (95% CI, 0.28--0.58) and the specificity was 0.95 (95%CI, 0.91--0.97). The LR+ and LR- were 7.90 (95% CI, 4.70--13.40), 0.61 (95% CI, 0.46--0.79), respectively. The AUC was 0.89 (95% CI, 0.86--0.92). The forest plots and SROC are shown in [Fig. 3](#pone.0116744.g003){ref-type="fig"} and [Fig. 4](#pone.0116744.g004){ref-type="fig"}, respectively.

![Forest plot of the accuracy of anti-M3R antibody for the diagnosis of SS.](pone.0116744.g003){#pone.0116744.g003}

![SROC of the accuracy of anti-M3R antibody for the diagnosis of SS.](pone.0116744.g004){#pone.0116744.g004}

Multiple regression analysis and exploration for heterogeneity {#sec003d}
--------------------------------------------------------------

Meta-regression analysis was conducted to explore possible sources of heterogeneity across the included studies. The following co-variates were evaluated as predictor variables: region; QUADAS score; peptide; coupling of peptide; confirmation of peptide; and diagnosis criteria. Results indicated that the variables we analyzed did not essentially affect the diagnostic accuracy of anti-M3R antibodies in SS ([Fig. 5](#pone.0116744.g005){ref-type="fig"}).

![Multiple regression analysis of included studies.](pone.0116744.g005){#pone.0116744.g005}

A Spearman rank correlation was also performed to confirm threshold effect; indication of threshold effect was found (Spearman correlation coefficient = 0.173, P = 0.440). In addition, the slope (b) of the regression equation did not differ from zero (P = 0.405), implying no heterogeneity among studies.

Publication bias {#sec003e}
----------------

The presence of a statistically significant slope coefficient (P \<0.05) was considered to indicate possible bias. We conducted funnel plots that represented a somewhat symmetric curve ([Fig. 6](#pone.0116744.g006){ref-type="fig"}). The slope coefficient was calculated to be 9.38±13.13, P = 0.48, indicating that no publication bias was observed in the included studies.

![Funnel plot of included studies.](pone.0116744.g006){#pone.0116744.g006}

Discussion {#sec004}
==========

The diagnosis of SS mainly relies on the triad of clinical characteristics, results of autoantibody test results, and histological assessment. However, the common clinical manifestations, dry eyes and dry mouth, are not specific to SS. Furthermore, while histology is considered the "gold standard" for the diagnosis of SS, the invasive nature of biopsy limits its widespread application. Anti-SSA and-SSB antibody are widely accepted diagnostic biomarkers for SS; however, the diagnostic performance is not considered satisfactory, despite a high specificity, as sensitivity is relatively low \[[@pone.0116744.ref002]\]. Emerging autoantibodies have been explored as complementary diagnostic biomarkers, in particular anti-M3R antibodies and anti-α-fodrin antibodies. Meta-analysis has previously been performed to evaluate the diagnostic performance of anti-α-fodrin antibodies in SS; results indicated a poor sensitivity (39%) but a high specificity (83%) \[[@pone.0116744.ref016]\]. To date, no systemic evaluation of the anti-M3R antibody has been performed. This study is the first meta-analysis to provide precise and controlled data on the diagnostic performance of anti-M3R antibody in SS.

Anti-M3R antibody was found to be a potential diagnostic biomarker of SS, and its diagnostic performance needs to be confirmed. There were 11 eligible studies of high quality (QUADAS scores \>7, [Fig. 2](#pone.0116744.g002){ref-type="fig"}) included in this meta-analysis ([Table 1](#pone.0116744.t001){ref-type="table"}). The pooled specificity was high (0.95), in comparison with a relatively low pooled sensitivity (0.43), which revealed that the diagnostic performance of anti-M3R antibody could identify controls better than anti-α-fodrin antibodies. The SROC curve implies anti-M3R antibodies showed moderate diagnostic performance for SS. The pattern of the points in the SROC curve did not suggest a 'shoulder-arm' shape, and the AUC of SROC was 0.89 (95% CI, 0.86--0.92). Taken together, these results indicate that anti-M3R antibody had a modest level of overall diagnostic accuracy for SS.

In order to explore the heterogeneity found across studies (P\<0.001, *I* ^2^ = 99%), meta-regression analysis and Spearman rank correlation were performed. We considered these variables might lead to the heterogeneity: Firstly, it's commonly recognized that different part of the M3R peptide, or M3R peptide coupling with or without larger molecular, or different modification of confirmation (linear/circular) have diverse antigenicity. Thus, we summarized the peptide that used in the detection of anti-M3R antibody ([Table 1](#pone.0116744.t001){ref-type="table"}). Results showed that most studies used synthetic linear peptide from the second extracellular loop of the M3R, no heterogeneity was found between the researches that used different peptides; Secondly, previous research reported that there is different incidence of SS between Chinese and Japanese, however, we didn't found heterogeneity among all the regions; Thirdly, different diagnosis criteria were applied among these studies, which might lead to the heterogeneity of included patients and eventually affected the diagnosis accuracy of anti-M3R antibody. Also no statistical heterogeneity was found. The last but not the least, different QUADAS score of the included studies did not influence the diagnostic accuracy of anti-M3R antibodies.

Some limitations in this meta-analysis need to be noted. Since not all the included studies provided clinical information, we did not evaluate the effect of different clinical manifestation of the disease, which may introduce analysis bias. In addition, we did not compare the diagnostic accuracy of anti-M3R antibody with the accuracy of anti-SSA and-SSB antibodies for the lack of researches.

In conclusion, anti-M3R antibodies are a modestly effective diagnostic biomarker for SS, with a low sensitivity but a high specificity. Combing anti-SSA, -SSB, and -M3R antibody assays may enhance diagnostic performance, and decrease the misdiagnosis rate.
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